Evolus (EOLS) Stock Forecast & Price Target

Evolus Inc. reported a 3.7% year-over-year increase in total net revenue, reaching $69.4 million, primarily driven by enhanced Jeuveau volumes and a successful launch of the Evolysse dermal filler line. The company's outlook for the Evolysse line reflects increased confidence, projecting a 10-12% contribution to the 2025 top-line guidance, translating to approximately $33 million. Additionally, there is a robust belief in significant market growth, fueled by younger consumers' favorable attitudes toward aesthetic treatments, which positions Evolus favorably within the evolving landscape of the self-pay aesthetic market.

Evolus Inc. has experienced a decline in adjusted gross margin, dropping to 66.5% from 71.5% year-over-year, attributed primarily to increased international sales and pricing strategies aimed at quickening product adoption. The company has revised its 2025 net revenue guidance down to $295-$305 million, reflecting a significant reduction in expected growth rates from 30%-33% to just 11%-15%. Furthermore, Jeuveau's second-quarter sales of $59.0 million marked a year-over-year decline for the first time since its launch, indicating weakening consumer sentiment and adverse trends in the broader U.S. aesthetic market.